Download PDF

下载PDF

Abstract selected as poster presentation during the Society for Immunotherapy of Cancer (SITC) Annual Meeting shows potent antitumor activity of CAN-3110 in preclinical models of melanomaCAN-3110's activity is designed to be conditional to the expression of Nestin in cancer cells and is associated with dual activity for oncolysis and immune activationFindings support potential indication expansion for CAN-3110 beyond high-grade glioma into melanoma, another Nestin-expressing solid tumor NEEDHAM, Mass., Nov.

摘要在癌症免疫治疗学会（SITC）年会上被选为海报展示，显示了CAN-3110在黑色素瘤临床前模型中的有效抗肿瘤活性-3110的活性被设计为以癌细胞中巢蛋白的表达为条件，并且与溶瘤和免疫激活的双重活性相关。发现支持CAN-3110从高级胶质瘤扩展到黑色素瘤的潜在适应症，这是另一种表达巢蛋白的实体瘤NEEDHAM，Mass。，11月。

05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced preclinical results and therapeutic potential of CAN-3110 in the Ras-Raf pathway altered melanoma model.

2024年5月5日（环球通讯社）--Candel Therapeutics，Inc.（Candel或该公司）（纳斯达克：CADL），一家临床阶段的生物制药公司，专注于开发多模式生物免疫疗法以帮助患者对抗癌症，今天宣布了CAN-3110在Ras-Raf途径改变的黑色素瘤模型中的临床前结果和治疗潜力。

The data will be presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place November 6-10, in Houston, Texas by Anne R. Diers, PhD, Senior Director of Research at Candel Therapeutics. CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation.

这些数据将由Candel Therapeutics高级研究主任Anne R.Diers博士在11月6日至10日于德克萨斯州休斯顿举行的癌症免疫治疗学会（SITC）第39届年会上发表。CAN-3110是一流的具有复制能力的单纯疱疹病毒-1（HSV-1）溶瘤病毒免疫治疗候选药物，具有溶瘤和免疫激活的双重活性。

CAN-3110 activity is conditional to the expression of Nestin in cancer cells and specific genetic alterations such as loss of the tumor suppressor gene CDKN2A. The poster, titled “Therapeutic potential of CAN-3110 in Ras-Raf pathway altered melanoma,” will focus on new data demonstrating the mechanism of action and antitumor activity of CAN-3110 in preclinical models of melanoma, a tumor characterized by high Nestin expression, frequent loss-of-function in CDKN2A, and additional alterations in the Ras-Raf signaling pathway.

CAN-3110的活性取决于癌细胞中巢蛋白的表达和特定的遗传改变，例如肿瘤抑制基因CDKN2A的丢失。这张题为“CAN-3110在Ras-Raf通路改变的黑色素瘤中的治疗潜力”的海报将重点关注新的数据，这些数据证明了CAN-3110在黑色素瘤临床前模型中的作用机制和抗肿瘤活性，黑色素瘤是一种以高巢蛋白表达为特征的肿瘤，CDKN2A功能的频繁丧失以及Ras-Raf信号通路的其他改变。